Call Us: 888-488-5750

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Leading the Way in Rebate Management

For over eight years, we’ve been at the forefront of rebate management. Our commitment to data integrity, compliance, and security has been unwavering. We pride ourselves on maintaining the highest standards of professional and ethical conduct, ensuring our partners and clients receive unparalleled service.

More Than Just Service Providers

VativoRx is not just another service provider in the vast healthcare landscape. We envision ourselves as partners. As we join the MHA community, our objective is to further solidify our commitment to the healthcare community in Michigan. Together, we aim to ensure operational excellence, financial robustness, and a brighter future for healthcare facilities across the state.

Driving Unparalleled Value

Our comprehensive approach guarantees that healthcare facilities have the opportunity to maximize their rebate revenues and achieve significant financial gains. With our dedicated team, innovative solutions, and a passion for excellence, we are here to deliver tangible results.

Looking Ahead

As we embark on this exciting new journey with MHA, we’re optimistic about the possibilities that lie ahead. We’re eager to work closely with other MHA members, share insights, learn from one another, and collectively drive the healthcare industry forward.

For more details about our collaboration and how VativoRx is shaping the future of rebate management, check out the official announcement here.


Stay tuned for more updates and insights from VativoRx. Together, we’re making healthcare better, one step at a time.

When Drug Negotiation Reaches Part B

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

Read More »

TrumpRx: What It Is and What to Watch

TrumpRx.gov has quickly become part of the national conversation on prescription affordability. For provider organizations, the value in tracking TrumpRx isn’t political; it’s operational. Programs like this can influence patient expectations, pricing conversations at the point of care, and the way stakeholders interpret “drug cost” when list, net, and out-of-pocket prices don’t align.

Read More »